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Abstract
Purpose:  The  aim  of  our  study  was  to  assess  the  results  and  cost  of  a  treatment  strategy
involving transarterial  chemoembolisation  with  drug  eluting  beads  (DEB-TACE)  in  patients  with
unresectable  non-metastatic  hepatocellular  carcinoma  (HCC).
Patients  and  methods:  This  study  included  all  patients  treated  with  DEB-TACE  in  our  hospital
between  January  2009  and  December  2010.  All  patients  received  DEB-TACE  on  demand  and
were evaluated  after  each  session.
Results:  Twenty-one  patients  received  an  average  of  1.3  sessions.  The  median  time  to  treatment
discontinuation  and  median  progression-free  survival  was  181  days  and  295  days,  respectively.
Toxicity caused  treatment  discontinuation  in  three  patients  (14%).  For  the  hospital,  the  aver-
age direct  cost  of  treatment  was  D  6,033  according  to  the  analytical  accounting  system  vs.
D 4,558  according  to  the  ofﬁcial  tariffs  from  the  new  French  Diagnosis-Related  Group  prospec-
tive payment  system  (P  =  0.002).
Conclusion:  In  the  treatment  of  HCC,  on-demand  DEB-TACE  stabilises  the  disease  in  some
patients  but  has  not  yet  been  th
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bbreviations
A  analytical  accounting
FP  alpha  foetoprotein
CLC  Barcelona  Clinic  Liver  Cancer
ACE  transarterial  chemoembolisation
DMP  blood-derived  medicinal  products
R  complete  response
U  care  unit
EB-TACE  drug  eluting  bead  transarterial  chemoembolisa-
tion
ASL European  Association  for  Study  of  the  Liver
XH daily  supplement  for  extra-long  hospital  stays
RG  diagnosis-related  group  (basic  medical/economic
classiﬁcation  category)
HS groupe  homogène  de  séjours  (tariffs  from  the  new
French  Diagnosis-Related  Group)
CC hepatocellular  carcinoma
CV hepatitis  C  virus
GE hepato-gastroenterology
CS daily  intensive  care  supplement
BP labile  blood  products
RI magnetic  resonance  imaging
ASH non-alcoholic  steatohepatitis
CI-CTC  AE  National  Cancer  Institute  Common  Toxicity
Criteria  for  Adverse  Events
FS progression-free  survival
R partial  response
D  standard  deviation
MD  sterile  medical  devices
2A  tariﬁcation  à  l’activité  (national  per-stay  prospec-
tive  payment  system)
ntroduction
ith  about  700,000  deaths  in  2008,  HCC  is  the  third  lead-
ng  cause  worldwide  of  mortality  from  cancer  [1].  Seventy
er  cent  of  patients  are  diagnosed  at  an  advanced  stage
nd  can  no  longer  beneﬁt  from  curative  treatment  (surgi-
al  resection,  liver  transplantation,  percutaneous  ablation)
2].  TACE  is  the  treatment  recommended  in  patients  with
n  unresectable,  non-metastatic  HCC  who  are  in  a  good
eneral  condition  with  preserved  hepatic  function  (inter-
ediate  stage  B  of  the  BCLC  classiﬁcation)  [2].  TACE  relies
n  both  local  provision  of  the  anticancer  agent  and  on  the
ual  arterial  and  venous  supply  to  the  liver  making  it  pos-
ible  to  temporarily  interrupt  arterial  ﬂow  without  inducing
schaemic  necrosis  of  the  organ.  Two  randomised  phase
II  trials  and  two  meta-analyses  have  demonstrated  that
ACE  increases  survival  in  patients  with  unresectable,  non-
etastatic  HCC,  compared  with  intravenous  chemotherapy
nd  supportive  care  [3—6]. Even  though  TACE  has  been  prac-
ised  throughout  the  world  for  many  years,  the  technique  is
till  very  heterogeneous,  and  depends  on  the  centres  and
adiologists  in  charge  of  the  procedure  for  the  choice  of
nticancer  agents,  the  doses,  the  vectors,  the  embolisa-
ion  agents,  the  perfusion  procedures  and  the  frequency
f  the  courses  [7].  This  heterogeneous  management  prob-
bly  explains  why  a  recent  meta-analysis  failed  to  conclude
o
i
h
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hat  TACE  was  superior  to  symptomatic  treatment  in  patients
ith  HCC  [8].
Since  2006,  new  medical  devices,  drug-eluting  beads
DEB),  have  been  used  as  the  vector  for  anticancer  agents
or  TACE  of  HCC.  These  expensive  devices  have  the  twin
dvantages  of  reducing  the  systemic  release  of  the  anti-
ancer  agent  by  releasing  it  in  a  controlled  way  on  contact
ith  the  tumour  and  of  embolising  the  vessels  supplying
he  hypervascularised  nodules.  These  two  advantages  are
till  theoretical  in  as  far  as  the  only  randomised  study  pub-
ished,  which  compared  the  efﬁcacy  and  tolerance  of  TACE
ith  doxorubicin-eluting  beads  with  conventional  TACE  using
ipiodol  as  the  vector,  did  not  demonstrate  any  signiﬁcant
ifference  in  terms  of  efﬁcacy  at  6  months  between  the  two
echniques  [9].  Moreover,  only  one  economic  study  com-
ared  the  cost  of  DEB-TACE  with  conventional  TACE,  but  it
nly  provided  information  on  the  costs  of  the  ﬁrst  course
10].  The  aim  of  our  work  was  to  evaluate  the  result  and
verall  cost  of  a  treatment  strategy  in  patients  with  unre-
ectable,  non-metastatic  HCC  using  DEB-TACE.
atients and methods
atients
ur  retrospective  study  included  all  the  patients  with  HCC
n  whom  treatment  by  DEB-TACE  had  been  initiated  in
ur  hospital  between  1st  January  2009  and  31st  December
010.  The  indication  for  treatment  with  DEB-TACE  was  sys-
ematically  determined  during  the  weekly  multidisciplinary
igestive  oncology  consultation  meetings  in  the  presence  of
t  least  a  radiologist,  a  gastroenterologist,  a  liver  surgeon,
 radiotherapist  and  an  oncologist.  The  patients  presented
nresectable,  non-metastatic,  uni-  or  paucifocal  (less  than
r  equal  to  three  nodules)  HCC  according  to  the  EASL
riteria,  with  preserved  hepatic  function  (Child  A  or  B7),
atisfactory  renal  function  (serum  creatinine  level  less  than
r  equal  to  1.5  times  the  upper  limit  of  normal),  a  left  ven-
ricular  ejection  fraction  of  more  than  50%  and  no  vascular
ontraindications  to  TACE  [11].
reatment
he  DEB-TACE  strategy  adopted  was  on  demand.  The
atients  received  one  course  and  were  retreated  depend-
ng  on  their  response  to  the  ﬁrst  course,  and  so  on  after
ach  course.  The  later  courses  were  given  every  2  months.
he  treatment  was  discontinued  in  the  event  of  toxicity  that
ontraindicated  its  resumption,  if  the  patient  refused  it,
f  imaging  showed  progression  or  if  the  response  allowed
imple  monitoring  or  curative  treatment  (resection,  liver
ransplantation,  percutaneous  ablation).  The  DEB-TACE  pro-
edure  took  place  in  the  interventional  radiology  room  of
he  Department  of  Radiology  of  our  hospital,  according  to
 standard  protocol.  Following  femoral  catheterisation  and
omplete  vascular  exploration  (evaluation  of  the  hepatic
ascularisation  and  the  accessory  vascularisation),  the  radi-
logist  injected  the  loaded  beads  within  20  minutes,  by
ntra-arterial  injection  into  the  right  or  left  branch  of  the
epatic  artery,  whichever  supplied  the  greater  part  of  the
umoral  mass,  as  selectively  as  possible,  and  sometimes
ting  
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extremely  selectively  by  using  a  ProgreatTM 2.7  Fr  micro-
catheter  (reference  MC-PP27131,  coaxial  with  an  integrated
guide,  Terumo,  Guyancourt,  France).  At  each  session,  the
patients  received  a  ﬁxed  dose  of  50  mg  of  doxorubicin
(Doxorubicin® 2  mg/ml,  Teva,  Paris,  France)  irrespective
of  their  weight  or  height.  Doxorubicin  was  loaded  into
25  mg  of  eluting  beads  (HepaSphereTM,  Biosphere  Medical,
Roissy,  France)  in  our  hospital  pharmacy.  The  solution  with
the  DEB  was  presented  in  a  60  ml  syringe.  Before  injec-
tion,  the  interventional  radiologist  added  20  ml  of  iodixanol
(Visipaque® 270  mg  I/ml,  GE  Healthcare,  Velizy,  France)
from  a  three-way  tap,  simply  inverting  the  syringe  to  make
a  uniform  mixture.  The  total  volume  theoretically  injected
into  the  patient  was  45  ml.  Prophylaxis  with  ceftriaxone
(Rocephine®,  Roche,  Neuilly,  France)  1  g/d  for  5  days  start-
ing  on  the  day  of  the  TACE  procedure  was  systematic,  in  the
absence  of  any  known  allergy.
The  response  to  treatment  was  assessed  by  MRI  or  CT
scan  with  contrast  injection,  according  to  the  EASL  criteria,
6  weeks  after  each  course  [11]. Deﬁnitions  of  the  responses
were:  CR,  disappearance  of  the  target  lesions  (absence  of
contrast  uptake  in  the  arterial  phase);  PR,  reduction  of  more
than  50%  in  the  size  of  the  viable  target  lesions;  progression,
increase  of  more  than  25%  in  the  size  of  the  viable  target
lesions  or  appearance  of  new  lesions;  stabilisation  of  the
disease  in  all  other  cases.  Toxicity  was  evaluated  following
each  course  according  to  the  NCI-CTC  AE  version  3.0.
Economic analysis
The  economic  analysis  was  conducted  from  a  hospital  point
of  view  from  the  ﬁrst  course  of  DEB-TACE  with  loaded  beads
until  treatment  discontinuation.  For  each  patient,  we  iden-
tiﬁed  all  the  stays  and  counted  the  number  of  days  of
hospitalisation  related  to  the  overall  management  of  their
HCC  and  all  the  resources  consumed  during  these  different
stays.
Periods  of  hospitalisation  took  into  account  patients’
stays  in  the  different  units  visited  that  is  to  say,  stays
in  the  HGE  unit  for  administration  of  DEB-TACE  and  stays
in  other  units  for  the  treatment  of  toxicity  related  to
this  particular  TACE  treatment.  Consultations  and  imag-
ing  sessions  were  not  included.  The  main  direct  medical
resources  consumed  by  patients  during  their  various  stays
were  identiﬁed  from  the  patients’  hospitalisation  ﬁles  or
from  nominative  data  recorded  by  the  pharmacy.  They
included  the  SMD  (microspheres  and  microcatheter),  the
medicinal  products  ﬁnanced  in  addition  to  the  tariffs  of  the
new  French  Diagnosis-Related  Group  (DRG)  payment  system,
labile  blood  products  (LBP)  and  blood-derived  medicinal
products  (BDMP).  The  costly  medicinal  products  ﬁnanced  in
addition  to  the  GHS  tariffs  were  identiﬁed  from  the  list  ﬁxed
by  the  ministerial  decree  of  4th  April  2005  and  updated  [12].
The  costs  were  evaluated  by  two  costing  methods:  Analyt-
ical  Accounting  (AA)  used  in  our  hospital  and  the  national
GHS  tariff  of  the  T2A  activity-based  costing  system  (national
per-stay  prospective  payment  system).  The  overall  hospital-
isation  costs  according  to  the  AA  of  our  hospital  included
all  the  partial  costs  of  hospitalisation  of  each  CU  visited
by  the  patient  during  the  management  of  his/her  HCC.
The  partial  cost  corresponded  to  the  running  costs  of  the
care  units  (CUs)  in  which  each  patient  was  hospitalised  (net
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irect  charges,  medical/technical  costs,  food  and  accom-
odation  and  logistics  costs).  This  excluded  pharmaceutical
xpenditure  (SMD,  medicines  ﬁnanced  in  addition  to  the
HS,  LBP  and  BDMP)  of  the  CUs  concerned,  for  which  the
ost  of  products  actually  consumed  was  recorded  patient
y  patient.  Resources  were  cost  from  unit  prices  obtained
n  2009  and  2010  when  calls  for  tenders  were  issued  and
ontracts  negotiated  for  medicinal  products,  and,  accord-
ng  to  the  tariffs  published  in  the  Ofﬁcial  Journal  in  2009
nd  2010  for  LBP  distributed  by  the  Établissement  Franc¸ais
u  Sang  [13]. The  price  of  a  vial  of  25  mg  HepaSphereTM was
 526  including  tax  in  2009  and  D  693  including  tax  in  2010.
he  price  of  the  embolisation  microcatheter  (ProgreatTM
.7  Fr,  reference  MC-PP27131  with  integrated  guide)  was
365  including  tax  in  2009  and  2010.  In  order  to  evaluate  the
ost  according  to  the  national  GHS  tariffs,  each  extremely
ong  stay  was  recorded  as  the  number  of  days  of  hospitali-
ation  exceeding  the  ‘‘upper  limit’’  set  for  each  GHS  [14].
ach  hospitalisation  period  included  only  one  of  the  incom-
lete  days  of  hospitalisation  (the  day  of  admission  counted
s  a  complete  day  whereas  the  day  of  discharge  was  not
ounted).  The  number  of  days  of  hospitalisation  was  estab-
ished  for  each  stay.  This  valuation  method  used  the  T2A
emuneration  rates,  i.e.  the  hospitalisation  tariffs  for  2009
nd  2010  ﬁxed  by  ministerial  decree  for  each  GHS.  The
nique  medical/economic  classiﬁcation  of  patients  (DRG)
ssigned  to  each  of  these  hospital  stays  was  provided  by
ur  hospital’s  Medical  Information  Department.  Three  dif-
erent  versions  of  the  DRG  classiﬁcation  were  used  (versions
10c,  V11  and  V11c)  depending  on  the  date  of  inclusion  of
he  patients  [15—17]. The  GHS  tariffs  were  ﬁxed  by  the  min-
sterial  decree  in  force  for  the  year  concerned  [18—20]. Any
XH,  ICS  supplements  and  the  cost  of  expensive  molecules
units  used  ×  unit  price)  were  taken  into  account.
tatistical analysis
eans  are  presented  with  their  ±  SD.  Frequency  was  com-
ared  using  the  Chi-squared  test  or  the  Fisher  exact
est.  Means  were  compared  using  the  Kruskal-Wallis  non-
arametric  test.  The  time  to  treatment  failure  was  deﬁned
s  the  time  between  the  date  of  the  ﬁrst  course  of  DEB-
ACE  and  the  date  treatment  was  discontinued  for  any
eason  (toxicity,  refusal  by  the  patient,  progression,  death).
atients  who  underwent  curative  treatment  were  excluded
rom  the  date  of  the  curative  treatment.  Progression-free
urvival  (PFS)  was  deﬁned  as  the  time  between  the  date
f  the  ﬁrst  course  of  DEB-TACE  and  the  date  of  progres-
ion.  The  survival  curve  was  plotted  using  the  Kaplan-Meier
ethod.  Statistical  analysis  used  the  STATA® program  ver-
ion  11  (StataCorp,  Texas,  USA).  The  signiﬁcance  level  was
et  at  P  =  0.05.
esults
aseline characteristics of the patientswenty-one  patients  (17  men  and  four  women)  were
ncluded  in  our  study.  The  patients  were  between  55  and
8  years  old  with  a  mean  of  72  years  of  age.  Eighty-six  per
ent  of  these  patients  presented  Child  A  cirrhosis.  In  the
56  
Table  1 Baseline  characteristics  of  the  patients.
n  (%)  Median  Mean  ±  SD
Age  (years) 74  72  ±  9
Sex
Male  17  (81)
Female 4  (19)
Aetiology  of  the  HCC
Alcohol  +  NASH 10 (47)
Alcohol 4 (19)
HCV 3 (14)
NASH  2  (10)
Healthy  liver  2  (10)
Prior  treatment
Yes  4  (19)
No 17 (81)
Number  of  nodules  1  1.7  ±  1.0
Size  of  the  largest
nodule  (mm)
46  55  ±  41
Total  tumour  size
(mm)
55  68  ±  41
Unilobar  HCC
Yes  15  (71)
No  6  (29)
AFP  (g/l)  5  103  ±  261
Performance  status
0  15  (71)
1  6  (29)
Child  score
A  18  (86)
B7  3  (14)
BCLC  score
A  2  (10)
B  13  (61)
C  6  (29)
AFP: alpha foetoprotein; BCLC: Barcelona Clinic Liver Cancer;
NASH: non-alcoholic steatohepatitis; SD: standard deviation.
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Figure 1. Hepatic MRI of a patient treated with doxorubicin-eluting 
complete necrosis.L.  Vadot  et  al.
ajority  of  patients  (67%),  the  aetiology  of  the  cirrhosis  was
lcoholic  or  alcohol/metabolic.  The  median  number  of  nod-
les  was  1  (mean  1.7  ±  1.1)  with  a  median  total  tumour  size
or  all  nodules  of  55  mm.  The  baseline  characteristics  of  the
atients  are  given  in  Table  1.
reatment
he  patients  received  a  mean  of  1.3  courses.  Sixteen
atients  (76%)  had  only  one  DEB-TACE  course.  Four  patients
19%)  had  two  courses  and  one  patient  (5%)  alone  had  three
ourses.  Seventeen  patients  (81%)  received  the  whole  dose
f  TACE  (45  ml),  four  patients  (19%)  received  at  least  two-
hirds  of  the  dose  (more  than  30  ml  injected,  i.e.  more  than
3  mg  of  doxorubicin).  Three  patients  (14%)  presented  tox-
city  contraindicating  continuation  of  the  treatment  while
ine  responding  patients  (43%)  were  simply  monitored  (n  =  2)
r  received  additional  treatment  (resection,  n  = 2;  percuta-
eous  ablation  using  radiofrequency  or  alcoholisation,  n  =  5).
he  hepatic  MRI  slices  from  a  patient  considered  a  very
ood  responder  to  DEB-TACE  courses  are  shown  in  Fig.  1.
he  median  time  to  treatment  failure  was  181  days.  Our
tudy  concerned  33  hospital  stays.  The  median  stay  for  the
rst  DEB-TACE  was  4  days  (mean  6  ±  5  days).  The  median
uration  of  all  the  stays  for  patients  receiving  treatment
y  DEB-TACE  was  7  days  (mean  8  ±  7  days).  After  a  mean
ollow-up  of  337  days,  ten  patients  (48%)  were  alive  with-
ut  progression.  Median  PFS  was  295  days  (Fig.  2).  The  PFS
ate  at  6  months  was  75%.  Three  patients  died  from  their
CC  during  the  study  period.  Our  study  reported  three  grade
—4  toxicities  leading  to  treatment  discontinuation  for  three
atients  (14%).  They  included  a  false  aneurysm  affecting  the
ight  superﬁcial  femoral  artery  and  two  oedematous  ascitic
ecompensations.  The  patient  with  the  vascular  complica-
ion  needed  a  surgical  procedure:  correction  of  the  false
neurysm  with  lateral  suturing  of  the  superﬁcial  femoral
rtery.  Other  cases  of  toxicity  observed  mainly  involved
light  fevers,  abdominal  pain  or  grade  1—2  vomiting  in  ten
atients  (48%)  in  the  48  hours  after  DEB-TACE.  The  rise  in
epatic  enzymes  remained  moderate.  No  patient  presented
beads: a: before treatment; b: six weeks post-treatment showing
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Table  2  Mean  costs  of  DEB-TACE  treatment.
Dijon  University  Hospitals  AA  GHS  hospitalisation  tariffs  P
Mean  (extremes) Mean  (extremes)
First  course  (D )  4265  (2449—13,833)  2674  (2092—5033) 0.01
Overall  strategy  (D )  6033  (2449—23,450) 4558  (2092—17,275) 0.002
AA: analytical accounting; GHS: groupe homogène de séjours (tariffs from the new French Diagnosis-Related Group).
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tion  of  DEB-TACE.
Economic analysis
Table  2  presents  the  costs  arising  from  one  or  more  hospi-
tal  stays  resulting  from  the  DEB-TACE  strategy,  according  to
both  our  hospital  AA  and  to  the  national  GHS  hospitalisation
tariff.  None  of  the  patients  in  our  study  received  medici-
nal  products  ﬁnanced  in  addition  to  the  GHS,  LBP  or  BDMP
during  their  treatment.  For  the  ﬁrst  course  of  DEB-TACE,
the  average  direct  medical  hospital  cost  of  treatment  was
D 4265  according  to  our  hospital  AA  vs.  D 2674  according  to
the  national  GHS  tariffs  (+D 1591,  P  =  0.01).  According  to  the
AA,  the  direct  medical  hospital  costs  of  an  overall  DEB-TACE
strategy  was  on  average  D 6033  vs.  D 4558  according  to  the
national  GHS  tariffs  (+D 1475,  P  =  0.002).
Discussion
To  date,  only  one  phase  II  randomised  study  has  compared
DEB-TACE  with  conventional  TACE  in  patients  with  HCC;
it  did  not  show  the  superiority  of  DEB-TACE  in  terms  of
response  rate  at  6  months  [9].  Other  studies  evaluating  the
efﬁcacy  and  tolerance  of  DEB-TACE  beyond  6  months  have
been  published  but  they  only  tested  regimens  with  courses
repeated  every  2  or  3  months  [21—26]. Our  study  is  thus  the
ﬁrst  to  provide  the  result  of  a  strategy  using  on-demand  DEB-
TACE  in  a  French  population  of  patients  with  unresectable,
non-metastatic  HCC.  We  have  been  applying  an  on-demand
Figure 2. Progression-free survival curve estimated by the
Kaplan-Meier technique.
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Atrategy  with  DEB-TACE  in  our  hospital  since  these  beads
ecame  available.  In  this  strategy,  the  response  obtained
fter  a  given  course,  evaluated  6  weeks  later  by  MRI,  deter-
ined  whether  the  patient  should  be  retreated  or  not  by
uccessive  courses.  At  the  present  time,  even  though  a
trategy  with  repeated  courses  of  TACE  appears  to  maxi-
ize  the  antitumour  activity,  it  has  not  been  proved  to  be
eally  more  effective,  whereas  it  is  more  toxic.  A  panel
f  HCC  experts  has  recently  recommended  an  on-demand
trategy  for  conventional  TACE,  but  did  not  give  any  opin-
on  on  DEB-TACE  [27]. Our  study  showed  a  median  PFS  of
pproximately  10  months  in  patients  with  unresectable,  non-
etastatic  HCC  treated  with  on-demand  DEB-TACE.  This
eems  to  be  comparable  with  the  median  PFS  reported  in
he  latest  randomised  TACE  trial,  which  tested  DEB-TACE
gainst  embolisation  alone  in  patients  with  HCC  [25]. In  this
rial,  median  PFS  for  patients  in  the  group  receiving  DEB-
ACE  was  12  months;  the  patients  received  courses  every
 months  with  a  maximum  of  three  courses.  In  terms  of  toler-
nce,  even  though  no  patient  died  of  complications  resulting
rom  DEB-TACE,  14%  of  them  discontinued  treatment  due
o  severe  toxicity.  In  the  Precision  V  study,  13%  of  patients
topped  treatment  with  DEB-TACE  because  of  severe  toxic-
ty  [9].  DEB-TACE  is  not  free  of  therapeutic  risk;  the  rate
f  treatment  discontinuation  due  to  toxicity  is  compara-
le  with  the  rates  observed  for  conventional  TACE,  i.e.  15
o  20%  [7].  Very  recently,  a  study  compared  the  frequency
f  severe  hepatic/and  or  biliary  toxicity  depending  on  the
ype  of  TACE  (lipiodol  or  drug  eluting  beads)  in  a  series  of
08  patients  treated  for  HCC  or  an  endocrine  tumour.  In
he  476  sessions  of  TACE  received  by  the  patients,  severe
epatic  and/or  biliary  toxicity  as  deﬁned  by  the  authors
ccurred  after  82  sessions  (17%).  In  multivariate  analysis,
he  fact  of  having  received  DEB-TACE  was  signiﬁcantly  asso-
iated  with  severe  hepatic  and/or  biliary  toxicity  (OR  6.6;
 <  0.001)  [28]. However,  this  toxicity  was  more  frequently
ssociated  with  the  treatment  of  an  endocrine  tumour  (non-
irrhotic  liver)  than  with  HCC.  In  addition  the  patients  with
n  endocrine  tumour  had  received  a  less  selective  treat-
ent  than  the  patients  with  HCC.  The  lower  selectivity  of
EB-TACE  could  thus  explain  the  hepatic  and/or  biliary  tox-
city.
Eluting  beads  are  innovative  and  costly  medical  devices.
o  date,  only  one  study  has  considered  the  real  cost  of  a  ﬁrst
ourse  of  TACE  with  these  devices  [10]; our  study  is  thus  the
rst  to  evaluate  the  overall  cost  of  treatment  of  HCC  with
EB-TACE.  AA  accurately  determines  overall  costs  for  treat-
ng  HCC  as  regards  the  spending  incurred  by  our  hospital
29]. For  a  ﬁrst  course  of  DEB-TACE,  the  cost  determined  by
A  was  D  4265  as  against  D  3600  in  a  previous  study  [10];
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his  cost  difference  may  be  explained  by  the  small  num-
er  of  patients  treated  in  the  latter  investigation  (n  =  6).
n  our  study,  comparison  of  the  tariffs  assigned  by  the  GHS
ith  the  AA  of  our  hospital  showed  that  the  cost  for  manag-
ng  a  ﬁrst  course  is  statistically  insufﬁcient  (P  =  0.01).  This
ifference  has  already  been  pointed  out,  but  was  not  statis-
ically  signiﬁcant  in  the  earlier  study  [10]  and  illustrates  the
nderestimation  of  innovative  techniques  by  the  national
HS  tariff  system.
Our  study  provides  information  on  the  overall  cost  of
anaging  HCC  with  DEB-TACE  until  treatment  is  discontin-
ed.  We  have  taken  into  account  the  costs  arising  for  all
he  courses  of  DEB-TACE  as  well  as  the  costs  arising  from
tays  due  to  the  toxicity  of  DEB-TACE  courses.  This  eval-
ation  provides  information  on  the  overall  cost  regarding
eneﬁts  but  also  the  risks  of  DEB-TACE.  Our  study  showed
hat  the  overall  care  costs  are  not  correctly  assessed,  since
he  real  costs  amounted  to  D 6033  vs.  D 4558  allowed  by  the
ational  tariff  (P  =  0.002).  There  are  two  possible  reasons
xplaining  this  underestimate  of  costs.  Firstly,  the  procedure
as  been  coded  without  taking  into  account  the  technique
sed  (DEB-TACE  or  conventional  TACE)  and  is  not  classiﬁed  as
 separate  act.  The  stays  of  two  patients  treated  by  differ-
nt  techniques  were  therefore  classiﬁed  in  the  same  DRG.
econdly,  three  different  DRG  classiﬁcations  were  used  dur-
ng  our  study  period.  The  V10c  classiﬁcation  used  before
arch  2009  had  two  levels  of  severity  related  to  the  patient’s
omorbidities  or  advanced  age;  there  are  now  four  levels
f  severity  in  the  V11  and  modiﬁed  V11  classiﬁcations  for
atients  treated  after  March  2009.  The  impact  of  this  clas-
iﬁcation  has  been  shown  for  other  pathological  conditions
30].
onclusion
n  patients  with  unresectable  non-metastatic  HCC  treated
ith  on-demand  DEB-TACE,  we  report  a  median  PFS  of
0  months  and  a  14%  rate  of  treatment  discontinuation  for
oxicity.  The  cost  of  overall  management  of  an  on-demand
reatment  strategy  for  HCC  by  DEB-TACE  seems  to  be  poorly
alued  by  the  T2A.  This  is  probably  due  to  the  fact  that  no
hase  III  study  has  proved  the  superiority  of  DEB-TACE  over
onventional  TACE.  In  the  context  of  the  current  system
f  hospital  funding,  it  seems  essential  to  carry  out  com-
arative  medical/economic  evaluations  of  DEB-TACE  and
onventional  TACE  strategies  in  patients  with  unresectable
on-metastatic  HCC.
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